表紙
市場調查報告書

毒蕈鹼性乙醯膽鹼受體M2(CHRM2):開發中產品分析

Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 520770
出版日期 內容資訊 英文 76 Pages
訂單完成後即時交付
價格
Back to Top
毒蕈鹼性乙醯膽鹼受體M2(CHRM2):開發中產品分析 Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 76 Pages
簡介

本報告提供以毒蕈鹼性乙醯膽鹼受體M2(CHRM2)為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

毒蕈鹼性乙醯膽鹼受體M2(CHRM2);概要

毒蕈鹼性乙醯膽鹼受體M2(CHRM2);治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Allergan Plc
  • Anavex Life Sciences Corp
  • FemmePharma Global Healthcare Inc
  • Juniper Pharmaceuticals Inc
  • Karuna Pharmaceuticals Inc
  • TheraVida Inc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2061TDB

Summary

According to the recently published report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019'; Muscarinic Acetylcholine Receptor M2 (CHRM2) pipeline Target constitutes close to 8 molecules.

Muscarinic Acetylcholine Receptor M2 (CHRM2) - Muscarinic cholinergic receptor 2 is an acetylcholine receptor. It is expressed in various regions of the brain including the cerebellum, cerebral cortex, hippocampus, medulla, striatum, and thalamus, and in lung and prostate. It mediates smooth muscle contractility. Increase in M2 receptor has been associated with depression.

The report 'Muscarinic Acetylcholine Receptor M2 - Pipeline Review, H2 2019' outlays comprehensive information on the Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 1, 4 and 2 respectively. Report covers products from therapy areas Central Nervous System, Genito Urinary System And Sex Hormones, Cardiovascular, Dermatology, Genetic Disorders and Respiratory which include indications Alzheimer's Disease, Overactive Bladder, Depression, Parkinson's Disease, Amnesia, Amyotrophic Lateral Sclerosis, Angelman Syndrome, Anxiety Disorders, Axillary Hyperhidrosis, Fragile X Syndrome, Infantile Spasm (West Syndrome), Movement Disorders, Multiple Sclerosis, Obstructive Sleep Apnea, Pain, Rett Syndrome, Schizophrenia, Stroke, Tuberous Sclerosis and Urinary Incontinence.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • The report reviews Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Muscarinic Acetylcholine Receptor M2 (CHRM2) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Muscarinic Acetylcholine Receptor M2 (CHRM2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Muscarinic Acetylcholine Receptor M2 (CHRM2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Overview
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Companies Involved in Therapeutics Development
  • Anavex Life Sciences Corp
  • Apnimed Inc
  • Dare Bioscience Inc
  • Dermavant Sciences Inc
  • FemmePharma Global Healthcare Inc
  • Karuna Therapeutics Inc
  • TheraVida Inc
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Drug Profiles
  • (atomoxetine + oxybutynin) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (oxybutynin + pilocarpine) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (pilocarpine + tolterodine) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (trospium chloride + xanomeline) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ANAVEX-141 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • blarcamesine hydrochloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • oxybutynin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • oxybutynin chloride - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • oxybutynin chloride ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Dormant Products
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Discontinued Products
  • Muscarinic Acetylcholine Receptor M2 (CHRM2) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 04, 2019: Anavex Life Sciences presents ANAVEX2-73 (blarcamesine) data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 conference
  • Nov 19, 2019: Karuna Therapeutics' schizophrenia drug passes Phase II trial
  • Nov 18, 2019: Karuna Therapeutics announces KarXT met primary endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
  • Nov 17, 2019: Karuna Therapeutics schedules webcast and conference call to announce results from its phase 2 clinical trial of KarXT for the treatment of Psychosis in patients with Schizophrenia
  • Nov 14, 2019: Anavex Life Sciences receives Rare Pediatric Disease Designation from FDA for ANAVEX2-73 (blarcamesine) for the treatment of Rett Syndrome
  • Nov 06, 2019: Anavex Life Sciences announces publication of foundational data for ANAVEX2-73 (blarcamesine) in Rett Syndrome
  • Oct 10, 2019: Anavex initiates ANAVEX 2-73 study in Alzheimer disease
  • Oct 02, 2019: Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX2-73 for the Treatment of Alzheimer's Disease
  • Sep 27, 2019: Anavex Life Sciences presented at the 6th Annual European Rett Syndrome Conference preliminary clinical efficacy data from the U.S. Rett Syndrome Phase 2 ANAVEX2-73 Study
  • Sep 16, 2019: Anavex Life Sciences announces preliminary clinical efficacy data of its U.S. phase 2 clinical trial of ANAVEX 2-73 in patients with Rett Syndrome
  • Sep 04, 2019: Anavex Life Sciences announces initiation of the EXCELLENCE ANAVEX 2-73-RS-003 clinical study in pediatric patients with Rett Syndrome
  • Jul 31, 2019: Anavex Life Sciences reports recent data review by the independent data safety monitoring board for its US phase 2 clinical trial of ANAVEX 2-73 in patients with Rett syndrome
  • Jul 29, 2019: Anavex Life Sciences receives positive opinion for orphan designation from the European Medicines Agency for ANAVEX2-73 for the treatment of rett syndrome
  • Jul 17, 2019: Anavex Life Sciences presents new clinical data identifying gut microbiota biomarkers asociated with improved clinical response in patients treated with ANAVEX2-73 at 2019 Alzheimer's Association International Conference (AAIC)
  • Jun 25, 2019: Anavex Life Sciences announces first patient dosed in extension study to its U.S. phase 2 clinical trial of ANAVEX2-73 in patients for Rett Syndrome
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Anavex Life Sciences Corp, H2 2019
  • Pipeline by Apnimed Inc, H2 2019
  • Pipeline by Dare Bioscience Inc, H2 2019
  • Pipeline by Dermavant Sciences Inc, H2 2019
  • Pipeline by FemmePharma Global Healthcare Inc, H2 2019
  • Pipeline by Karuna Therapeutics Inc, H2 2019
  • Pipeline by TheraVida Inc, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
Back to Top